The aim of this observational cross‑sectional study with retrospective review of the data is to evaluate the efficacy of using technetium‑99m‑octreotide (Tc‑99m‑OCT) in imaging neuroendocrine tumors (NETs) in our tertiary care hospital. A total of 58 patients had Tc‑99m‑OCT were identified in our database, from January 2013 to December 2016. Forty‑one patients (age range of 15–75 years) meet our inclusion criteria, namely histopathology proven NETs, Tc‑99m‑OCT scan, computed tomography (CT), or magnetic resonance imaging (MRI) done in our institute for correlation. Twenty‑three patients had true positive Tc‑99m‑OCT scan. In addition to the primary tumors, the octreotide scan revealed metastasis in the lung, liver, and retroperitoneal lymph nodes. The smallest lesion detected on octreotide scan was a 4‑mm pulmonary nodule that was missed on lung window CT scan. The Tc‑99m‑OCT had 17 true negative, one false negative, and no false positive. The CT and MRI scans had 18 true positive, 17 true negative, 5 false negative, and one false positive. The overall sensitivity, specificity, accuracy, positive, and negative predictive values of Tc‑99m‑OCT scan were 96%, 100%, 97%, 100%, and 94%, respectively. Whereas those of CT and MRI were 78%, 94%, 85%, 94%, and 77%, respectively. Our diagnostic accuracy of Tc‑99m‑OCT is high. We recommend that, in addition to the conventional radiological investigations, Tc‑99m‑OCT scan, or other somatostatin receptor imaging (SSR) is a mandate for better and accurate staging of patients with NETs.

The aim of this observational cross‑sectional study with retrospective review of the data is to evaluate the efficacy of using technetium‑99m‑octreotide (Tc‑99m‑OCT) in imaging neuroendocrine tumors (NETs) in our tertiary care hospital. A total of 58 patients had Tc‑99m‑OCT were identified in our ...